What is SNY's current stock price?

As of now, SNY is trading at $47.47, with a daily change of -0.88%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

SNY Stock Analysis & IQ Rating | Sanofi

SNY

Sanofi

$47.47

-$0.42 | -0.88%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$60.12

MKT CAP

$116.00B

52W Low

$44.62

VOL

$2.36M

P/E Ratio

11.02

AVG VOL

$2.84M

RSI

43.37

TREND

Downtrend

SNY Stock IQ

Login to see Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

SNY Target Price

Login to display

Strengths

SNY Rewards

Trading below its fair value

SNY Rewards

Upgraded on attractively valued

SNY Price Performance

$48.14 (-1.39%)

$49.73 (-4.54%)

$51.35 (-7.56%)

$54.34 (-12.64%)

1year

6month

3month

1month

SNY Risk Level

SNY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

Low

LOW

HIGH

SNY Analysts Opinion

SNY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

SNY Analysts Opinion

SNY Analysts opinion is positive and also has improved from the past 3 months

SNY Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

86%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

20%

90%

SNY Street Sentiment

SNY Street Sentiment is extremely bullish and have positive views on the near-term outlook

SNY Performance Sentiment

Sentiments overview associated with SNY events and the stock performance.

86%

14%

Positive

Negative

43 out of 50
events present

7 out of 50
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$47.89

Resistance
Price

$47.20

Current Price Range

$49.34

Show methods +

Linked to SNY

IQ

Close Price

Change

PFE

4.25

25.89

+1.21%

NVS

4.12

143.15

-2.06%

LLY

4.21

1032.97

-3.76%

REGN

4.14

741.92

-1.62%

MRK

4.24

110.95

-0.06%

Recently Viewed

Close Price

Change

SNY

Sanofi

47.47

-0.88%

AEG

Aegon NV

7.70

-1.03%

ARTL

Artelo Biosciences

1.66

+3.11%

AEO

American Eagle Outfitters

25.83

+0.56%

ARTW

Art's-Way Manufacturing C

2.37

-1.87%

SNY Latest Analysis +

Ocular Launches And Then Yo-Yoes On Rumors Sanofi Is Preparing A Bigger Bid. Shares of Ocular Therapeutix launched and then yo-yoed Thursday on reports Sanofi is preparing an improved bid to buy it.The post Ocular Launches And Then Yo-Yoes On Rumors Sanofi Is Preparing A Bigger Bid appeared first on Investor'.s Business Daily.

Today

$47.47 | -0.88%

Activity

Potential

Ocular Launches And Then Slides On Rumors Sanofi Is Preparing A Bigger Bid. Shares of Ocular Therapeutix launched and then retreated Thursday on reports Sanofi is preparing an improved bid to buy it.The post Ocular Launches And Then Slides On Rumors Sanofi Is Preparing A Bigger Bid appeared first on Investor'.s Business Daily.

Today

$47.47 | -0.88%

Activity

Momentum

Potential

Ocular Therapeutix Launches On Rumors Sanofi Is Preparing A Bigger Bid.

Today

$47.47 | -0.88%

Activity

Ocular surges on report of Sanofi buyout bid.

Today

$47.47 | -0.88%

Activity

Momentum

Press Release: Myqorzo and Redemplo approved in China. Myqorzo and Redemplo approved in ChinaParis January 15 2026. The National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) and Redemplo (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control. We are pleased to bring

Today

$47.47 | -0.88%

Activity

Sanofi Gains China NMPA Nod For Myqorzo And Redemplo In OHCM And FCS Treatments . (RTTNews) - Sanofi Winthrop Industrie announced that Chinas National Medical Products Administration (NMPA) has granted approval for two innovative Sanofi-licensed medicines. Myqorzo (aficamten) has been authorized for the treatment of obstructive hypertrophic cardiomyopathy (oH

Today

$47.47 | -0.88%

Activity

Sanofi receives China approval for Myqorzo and Redemplo drugs.

Today

$47.47 | -0.88%

Activity

Sandoz Secures European Commission Approval For Ondibta A Biosimilar To Lantus For Diabetes . (RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine) a biosimilar to Sanofis Lantus SoloStar for the treatment of diabetes mellitus across all indications of the reference medicine.

Wed Jan 14, 2026

$47.89 | +1.46%

Activity

Sanofis Teizeild Gets EU Approval for Treating Type 1 Diabetes. SNY wins EU approval for Teizeild the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.

Tue Jan 13, 2026

$47.20 | -0.84%

Activity

Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.

Mon Jan 12, 2026

$47.60 | -2.92%

Activity

FAQ About SNY Stock Insights

What is SNY current stock price?

What are SNY stock strengths?

What is SNY Risk Level?

What is SNY market cap and volume?

What is SNY current Stock IQ?

Should I buy SNY stock right now?

Is SNY a Strong Buy right now?

What does a 'Strong Buy' rating mean for SNY?

What does a 'Strong Sell' rating mean for SNY?

What factors influence SNY's Stock IQ?

Explore our SNY Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored SNY Stock Strategies
Effective Risk Management

FIND US ON

Receive our SNY Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

SNY

Sanofi

Set Alerts

Current Price

$47.47

-$0.42 | -0.88%

52W High

$60.12

MKT CAP

$116.00B

52W Low

$44.62

VOL

$2.36M

P/E Ratio

11.02

AVG VOL

$2.84M

RSI

43.37

TREND

Downtrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

SNY Stock IQ

Login to unlock Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

SNY Rewards

Trading below its fair value

SNY Rewards

Upgraded on attractively valued

Linked to SNY

Symbol

IQ

Close

Change

PFE

4.25

25.89

+1.21%

NVS

4.12

143.15

-2.06%

LLY

4.21

1032.97

-3.76%

REGN

4.14

741.92

-1.62%

MRK

4.24

110.95

-0.06%

SNY Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

86%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

20%

90%

SNY Street Sentiment

SNY Street Sentiment is extremely bullish and have positive views on the near-term outlook

SNY Risk Level

SNY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

Low

LOW

HIGH

SNY Performance Sentiment

Sentiments overview associated with SNY events and the stock performance.

86%

14%

Positive

Negative

43 out of 50
events present

7 out of 50
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$47.89

Resistance
Price

$47.20

Current Price Range

$49.34

Show methods +

SNY Latest Analysis

Ocular Launches And Then Yo-Yoes On Rumors Sanofi Is Preparing A Bigger Bid. Shares of Ocular Therapeutix launched and then yo-yoed Thursday on reports Sanofi is preparing an improved bid to buy it.The post Ocular Launches And Then Yo-Yoes On Rumors Sanofi Is Preparing A Bigger Bid appeared first on Investor'.s Business Daily.

Today

$47.47 | -0.88%

Activity

Potential

Ocular Launches And Then Slides On Rumors Sanofi Is Preparing A Bigger Bid. Shares of Ocular Therapeutix launched and then retreated Thursday on reports Sanofi is preparing an improved bid to buy it.The post Ocular Launches And Then Slides On Rumors Sanofi Is Preparing A Bigger Bid appeared first on Investor'.s Business Daily.

Today

$47.47 | -0.88%

Activity

Momentum

Potential

Ocular Therapeutix Launches On Rumors Sanofi Is Preparing A Bigger Bid.

Today

$47.47 | -0.88%

Activity

Ocular surges on report of Sanofi buyout bid.

Today

$47.47 | -0.88%

Activity

Momentum

Press Release: Myqorzo and Redemplo approved in China. Myqorzo and Redemplo approved in ChinaParis January 15 2026. The National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) and Redemplo (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control. We are pleased to bring

Today

$47.47 | -0.88%

Activity

Sanofi Gains China NMPA Nod For Myqorzo And Redemplo In OHCM And FCS Treatments . (RTTNews) - Sanofi Winthrop Industrie announced that Chinas National Medical Products Administration (NMPA) has granted approval for two innovative Sanofi-licensed medicines. Myqorzo (aficamten) has been authorized for the treatment of obstructive hypertrophic cardiomyopathy (oH

Today

$47.47 | -0.88%

Activity

Sanofi receives China approval for Myqorzo and Redemplo drugs.

Today

$47.47 | -0.88%

Activity

Sandoz Secures European Commission Approval For Ondibta A Biosimilar To Lantus For Diabetes . (RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine) a biosimilar to Sanofis Lantus SoloStar for the treatment of diabetes mellitus across all indications of the reference medicine.

Wed Jan 14, 2026

$47.89 | +1.46%

Activity

Sanofis Teizeild Gets EU Approval for Treating Type 1 Diabetes. SNY wins EU approval for Teizeild the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.

Tue Jan 13, 2026

$47.20 | -0.84%

Activity

Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.

Mon Jan 12, 2026

$47.60 | -2.92%

Activity

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of SNY. We're here to help you make informed investment decisions today.

FIND US ON

Receive our SNY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

SNY Stock trends

SNY Stock performance

SNY Stock analysis

SNY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

SNY Stock Analysis & IQ Rating | Sanofi

SNY Stock IQ

SNY Target Price

SNY Risk Level

SNY Analysts Opinion

SNY Street Sentiment

SNY Performance Sentiment

Technical Price Levels

Explore our SNY Stock insights

Receive our SNY Daily Alerts

SNY Street Sentiment

SNY Risk Level

Technical Price Levels

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of SNY. We're here to help you make informed investment decisions today.

Receive our SNY Daily Alerts

SNY Alerts